Teva expects to launch its Uzedy long-acting injectable risperidone product within weeks after receiving a long-awaited US Food and Drug Administration approval for the 505(b)(2) hybrid schizophrenia treatment.
Teva Prepares To Launch LAI Risperidone After US Approval
MedinCell-Partnered Schizophrenia Treatment Uzedy Has Now Been Approved By US FDA
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
